Global Biosimilars Market Research Report 2023(Status and Outlook)

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,800	156 Pages	Bosson Research	May, 2023	BOSS18171887

Best Price Guarantee
Price	from $2,800
Length	156 Pages
Publisher	Bosson Research
Published Date	May, 2023
SKU	BOSS18171887

Global Biosimilars Market Research Report 2023(Status and Outlook)

Report Overview

A biosimilar is a biologic medical product highly similar to another already approved biological medicine (the 'reference medicine'). Biosimilars are approved according to the same standards of pharmaceutical quality, safety and efficacy that apply to all biological medicines. Biosimilars are officially approved versions of original ""innovator"" products and can be manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.

The Global Biosimilars Market Size was estimated at USD 5727.5 million in 2022 and is projected to reach USD 18244.80 million by 2029, exhibiting a CAGR of 18.00% during the forecast period.

Bosson Research’s latest report provides a deep insight into the global Biosimilars market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Biosimilars Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Biosimilars market in any manner.

Global Biosimilars Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Pfizer

Novartis

Biocon

Biogen

Fresenius Kabi AG

Boehringer Ingelheim

Merck KgaA

Mylan

Eli Lilly

Teva Pharmaceutical

Dr. Reddy's Laboratories

Amgen

Celltrion

Samsung Biologics

Roche

Probiomed

Apotex

Chong Kun Dang

JCR Pharmaceuticals

Gan & Lee Pharmaceuticals

Gedeon Richter

Biocad

Coherus Bioscience

Stada Arzneimittel AG

Market Segmentation (by Type)

Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)

Recombinant Glycosylated Proteins

Market Segmentation (by Application)

Industrial Applications

Municipal Applications

Others

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Biosimilars Market

Overview of the regional outlook of the Biosimilars Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

1 Research Methodology and Statistical Scope: 1.1 Market Definition and Statistical Scope of Biosimilars; 1.2 Key Market Segments; 1.2.1 Biosimilars Segment by Type; 1.2.2 Biosimilars Segment by Application; 1.3 Methodology & Sources of Information; 1.3.1 Research Methodology; 1.3.2 Research Process; 1.3.3 Market Breakdown and Data Triangulation; 1.3.4 Base Year; 1.3.5 Report Assumptions & Caveats
2 Biosimilars Market Overview: 2.1 Global Market Overview; 2.1.1 Global Biosimilars Market Size (M USD) Estimates and Forecasts (2018-2029); 2.1.2 Global Biosimilars Sales Estimates and Forecasts (2018-2029); 2.2 Market Segment Executive Summary; 2.3 Global Market Size by Region
3 Biosimilars Market Competitive Landscape: 3.1 Global Biosimilars Sales by Manufacturers (2018-2023); 3.2 Global Biosimilars Revenue Market Share by Manufacturers (2018-2023); 3.3 Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3); 3.4 Global Biosimilars Average Price by Manufacturers (2018-2023); 3.5 Manufacturers Biosimilars Sales Sites, Area Served, Product Type; 3.6 Biosimilars Market Competitive Situation and Trends; 3.6.1 Biosimilars Market Concentration Rate; 3.6.2 Global 5 and 10 Largest Biosimilars Players Market Share by Revenue; 3.6.3 Mergers & Acquisitions, Expansion
4 Biosimilars Industry Chain Analysis: 4.1 Biosimilars Industry Chain Analysis; 4.2 Market Overview of Key Raw Materials; 4.3 Midstream Market Analysis; 4.4 Downstream Customer Analysis
5 The Development and Dynamics of Biosimilars Market: 5.1 Key Development Trends; 5.2 Driving Factors; 5.3 Market Challenges; 5.4 Market Restraints; 5.5 Industry News; 5.5.1 New Product Developments; 5.5.2 Mergers & Acquisitions; 5.5.3 Expansions; 5.5.4 Collaboration/Supply Contracts; 5.6 Industry Policies
6 Biosimilars Market Segmentation by Type: 6.1 Evaluation Matrix of Segment Market Development Potential (Type); 6.2 Global Biosimilars Sales Market Share by Type (2018-2023); 6.3 Global Biosimilars Market Size Market Share by Type (2018-2023); 6.4 Global Biosimilars Price by Type (2018-2023)
7 Biosimilars Market Segmentation by Application: 7.1 Evaluation Matrix of Segment Market Development Potential (Application); 7.2 Global Biosimilars Market Sales by Application (2018-2023); 7.3 Global Biosimilars Market Size (M USD) by Application (2018-2023); 7.4 Global Biosimilars Sales Growth Rate by Application (2018-2023)
8 Biosimilars Market Segmentation by Region: 8.1 Global Biosimilars Sales by Region; 8.1.1 Global Biosimilars Sales by Region; 8.1.2 Global Biosimilars Sales Market Share by Region; 8.2 North America; 8.2.1 North America Biosimilars Sales by Country; 8.2.2 U.S.; 8.2.3 Canada; 8.2.4 Mexico; 8.3 Europe; 8.3.1 Europe Biosimilars Sales by Country; 8.3.2 Germany; 8.3.3 France; 8.3.4 U.K.; 8.3.5 Italy; 8.3.6 Russia; 8.4 Asia Pacific; 8.4.1 Asia Pacific Biosimilars Sales by Region; 8.4.2 China; 8.4.3 Japan; 8.4.4 South Korea; 8.4.5 India; 8.4.6 Southeast Asia; 8.5 South America; 8.5.1 South America Biosimilars Sales by Country; 8.5.2 Brazil; 8.5.3 Argentina; 8.5.4 Columbia; 8.6 Middle East and Africa; 8.6.1 Middle East and Africa Biosimilars Sales by Region; 8.6.2 Saudi Arabia; 8.6.3 UAE; 8.6.4 Egypt; 8.6.5 Nigeria; 8.6.6 South Africa
9 Key Companies Profile: 9.1 Pfizer; 9.1.1 Pfizer Biosimilars Basic Information; 9.1.2 Pfizer Biosimilars Product Overview; 9.1.3 Pfizer Biosimilars Product Market Performance; 9.1.4 Pfizer Business Overview; 9.1.5 Pfizer Biosimilars SWOT Analysis; 9.1.6 Pfizer Recent Developments; 9.2 Novartis; 9.2.1 Novartis Biosimilars Basic Information; 9.2.2 Novartis Biosimilars Product Overview; 9.2.3 Novartis Biosimilars Product Market Performance; 9.2.4 Novartis Business Overview; 9.2.5 Novartis Biosimilars SWOT Analysis; 9.2.6 Novartis Recent Developments; 9.3 Biocon; 9.3.1 Biocon Biosimilars Basic Information; 9.3.2 Biocon Biosimilars Product Overview; 9.3.3 Biocon Biosimilars Product Market Performance; 9.3.4 Biocon Business Overview; 9.3.5 Biocon Biosimilars SWOT Analysis; 9.3.6 Biocon Recent Developments; 9.4 Biogen; 9.4.1 Biogen Biosimilars Basic Information; 9.4.2 Biogen Biosimilars Product Overview; 9.4.3 Biogen Biosimilars Product Market Performance; 9.4.4 Biogen Business Overview; 9.4.5 Biogen Biosimilars SWOT Analysis; 9.4.6 Biogen Recent Developments; 9.5 Fresenius Kabi AG; 9.5.1 Fresenius Kabi AG Biosimilars Basic Information; 9.5.2 Fresenius Kabi AG Biosimilars Product Overview; 9.5.3 Fresenius Kabi AG Biosimilars Product Market Performance; 9.5.4 Fresenius Kabi AG Business Overview; 9.5.5 Fresenius Kabi AG Biosimilars SWOT Analysis; 9.5.6 Fresenius Kabi AG Recent Developments; 9.6 Boehringer Ingelheim; 9.6.1 Boehringer Ingelheim Biosimilars Basic Information; 9.6.2 Boehringer Ingelheim Biosimilars Product Overview; 9.6.3 Boehringer Ingelheim Biosimilars Product Market Performance; 9.6.4 Boehringer Ingelheim Business Overview; 9.6.5 Boehringer Ingelheim Recent Developments; 9.7 Merck KgaA; 9.7.1 Merck KgaA Biosimilars Basic Information; 9.7.2 Merck KgaA Biosimilars Product Overview; 9.7.3 Merck KgaA Biosimilars Product Market Performance; 9.7.4 Merck KgaA Business Overview; 9.7.5 Merck KgaA Recent Developments; 9.8 Mylan; 9.8.1 Mylan Biosimilars Basic Information; 9.8.2 Mylan Biosimilars Product Overview; 9.8.3 Mylan Biosimilars Product Market Performance; 9.8.4 Mylan Business Overview; 9.8.5 Mylan Recent Developments; 9.9 Eli Lilly; 9.9.1 Eli Lilly Biosimilars Basic Information; 9.9.2 Eli Lilly Biosimilars Product Overview; 9.9.3 Eli Lilly Biosimilars Product Market Performance; 9.9.4 Eli Lilly Business Overview; 9.9.5 Eli Lilly Recent Developments; 9.10 Teva Pharmaceutical; 9.10.1 Teva Pharmaceutical Biosimilars Basic Information; 9.10.2 Teva Pharmaceutical Biosimilars Product Overview; 9.10.3 Teva Pharmaceutical Biosimilars Product Market Performance; 9.10.4 Teva Pharmaceutical Business Overview; 9.10.5 Teva Pharmaceutical Recent Developments; 9.11 Dr. Reddy's Laboratories; 9.11.1 Dr. Reddy's Laboratories Biosimilars Basic Information; 9.11.2 Dr. Reddy's Laboratories Biosimilars Product Overview; 9.11.3 Dr. Reddy's Laboratories Biosimilars Product Market Performance; 9.11.4 Dr. Reddy's Laboratories Business Overview; 9.11.5 Dr. Reddy's Laboratories Recent Developments; 9.12 Amgen; 9.12.1 Amgen Biosimilars Basic Information; 9.12.2 Amgen Biosimilars Product Overview; 9.12.3 Amgen Biosimilars Product Market Performance; 9.12.4 Amgen Business Overview; 9.12.5 Amgen Recent Developments; 9.13 Celltrion; 9.13.1 Celltrion Biosimilars Basic Information; 9.13.2 Celltrion Biosimilars Product Overview; 9.13.3 Celltrion Biosimilars Product Market Performance; 9.13.4 Celltrion Business Overview; 9.13.5 Celltrion Recent Developments; 9.14 Samsung Biologics; 9.14.1 Samsung Biologics Biosimilars Basic Information; 9.14.2 Samsung Biologics Biosimilars Product Overview; 9.14.3 Samsung Biologics Biosimilars Product Market Performance; 9.14.4 Samsung Biologics Business Overview; 9.14.5 Samsung Biologics Recent Developments; 9.15 Roche; 9.15.1 Roche Biosimilars Basic Information; 9.15.2 Roche Biosimilars Product Overview; 9.15.3 Roche Biosimilars Product Market Performance; 9.15.4 Roche Business Overview; 9.15.5 Roche Recent Developments; 9.16 Probiomed; 9.16.1 Probiomed Biosimilars Basic Information; 9.16.2 Probiomed Biosimilars Product Overview; 9.16.3 Probiomed Biosimilars Product Market Performance; 9.16.4 Probiomed Business Overview; 9.16.5 Probiomed Recent Developments; 9.17 Apotex; 9.17.1 Apotex Biosimilars Basic Information; 9.17.2 Apotex Biosimilars Product Overview; 9.17.3 Apotex Biosimilars Product Market Performance; 9.17.4 Apotex Business Overview; 9.17.5 Apotex Recent Developments; 9.18 Chong Kun Dang; 9.18.1 Chong Kun Dang Biosimilars Basic Information; 9.18.2 Chong Kun Dang Biosimilars Product Overview; 9.18.3 Chong Kun Dang Biosimilars Product Market Performance; 9.18.4 Chong Kun Dang Business Overview; 9.18.5 Chong Kun Dang Recent Developments; 9.19 JCR Pharmaceuticals; 9.19.1 JCR Pharmaceuticals Biosimilars Basic Information; 9.19.2 JCR Pharmaceuticals Biosimilars Product Overview; 9.19.3 JCR Pharmaceuticals Biosimilars Product Market Performance; 9.19.4 JCR Pharmaceuticals Business Overview; 9.19.5 JCR Pharmaceuticals Recent Developments; 9.20 Gan andamp; Lee Pharmaceuticals; 9.20.1 Gan andamp; Lee Pharmaceuticals Biosimilars Basic Information; 9.20.2 Gan andamp; Lee Pharmaceuticals Biosimilars Product Overview; 9.20.3 Gan andamp; Lee Pharmaceuticals Biosimilars Product Market Performance; 9.20.4 Gan andamp; Lee Pharmaceuticals Business Overview; 9.20.5 Gan andamp; Lee Pharmaceuticals Recent Developments; 9.21 Gedeon Richter; 9.21.1 Gedeon Richter Biosimilars Basic Information; 9.21.2 Gedeon Richter Biosimilars Product Overview; 9.21.3 Gedeon Richter Biosimilars Product Market Performance; 9.21.4 Gedeon Richter Business Overview; 9.21.5 Gedeon Richter Recent Developments; 9.22 Biocad; 9.22.1 Biocad Biosimilars Basic Information; 9.22.2 Biocad Biosimilars Product Overview; 9.22.3 Biocad Biosimilars Product Market Performance; 9.22.4 Biocad Business Overview; 9.22.5 Biocad Recent Developments; 9.23 Coherus Bioscience; 9.23.1 Coherus Bioscience Biosimilars Basic Information; 9.23.2 Coherus Bioscience Biosimilars Product Overview; 9.23.3 Coherus Bioscience Biosimilars Product Market Performance; 9.23.4 Coherus Bioscience Business Overview; 9.23.5 Coherus Bioscience Recent Developments; 9.24 Stada Arzneimittel AG; 9.24.1 Stada Arzneimittel AG Biosimilars Basic Information; 9.24.2 Stada Arzneimittel AG Biosimilars Product Overview; 9.24.3 Stada Arzneimittel AG Biosimilars Product Market Performance; 9.24.4 Stada Arzneimittel AG Business Overview; 9.24.5 Stada Arzneimittel AG Recent Developments
10 Biosimilars Market Forecast by Region: 10.1 Global Biosimilars Market Size Forecast; 10.2 Global Biosimilars Market Forecast by Region; 10.2.1 North America Market Size Forecast by Country; 10.2.2 Europe Biosimilars Market Size Forecast by Country; 10.2.3 Asia Pacific Biosimilars Market Size Forecast by Region; 10.2.4 South America Biosimilars Market Size Forecast by Country; 10.2.5 Middle East and Africa Forecasted Consumption of Biosimilars by Country
11 Forecast Market by Type and by Application (2024-2029): 11.1 Global Biosimilars Market Forecast by Type (2024-2029); 11.1.1 Global Forecasted Sales of Biosimilars by Type (2024-2029); 11.1.2 Global Biosimilars Market Size Forecast by Type (2024-2029); 11.1.3 Global Forecasted Price of Biosimilars by Type (2024-2029); 11.2 Global Biosimilars Market Forecast by Application (2024-2029); 11.2.1 Global Biosimilars Sales (K MT) Forecast by Application; 11.2.2 Global Biosimilars Market Size (M USD) Forecast by Application (2024-2029)
12 Conclusion and Key Findings